Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain.
HTLV-1
adult T-cell leukemia
epidemiology
myelopathy
screening
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
18
11
2018
accepted:
15
01
2019
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
1
3
2019
Statut:
epublish
Résumé
Although only 8%-10% of persons infected with human T-cell leukemia virus type 1 (HTLV-1) may develop virus-associated diseases lifelong, misdiagnosis of asymptomatic infected carriers frequently leads to late diagnoses. A nationwide HTLV-1 register was created in Spain in 1989. A total of 351 infected persons had been reported by the end of 2017. We examined all new HTLV-1 diagnoses during the last decade and compared their clinical presentation. A total of 247 individuals with HTLV-1 infection had been reported in Spain since year 2008. The incidence has remained stable with 20-25 new diagnoses yearly. Women represented 62%. Only 12% were native Spaniards, most of whom were foreigners from Latin America (72.5%). Up to 57 (23%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (n = 24; 42.1%), T-cell lymphoma (n = 19; 33.3%), or Given that 23% of new HTLV-1 diagnoses in Spain are symptomatic, underdiagnosis must be common. Although screening in blood banks mostly identifies asymptomatic Latin American carriers, a disproportionately high number of Spaniards and Africans are unveiled too late, that is, they already suffer from classic HTLV-1 illnesses.
Sections du résumé
BACKGROUND
BACKGROUND
Although only 8%-10% of persons infected with human T-cell leukemia virus type 1 (HTLV-1) may develop virus-associated diseases lifelong, misdiagnosis of asymptomatic infected carriers frequently leads to late diagnoses.
METHODS
METHODS
A nationwide HTLV-1 register was created in Spain in 1989. A total of 351 infected persons had been reported by the end of 2017. We examined all new HTLV-1 diagnoses during the last decade and compared their clinical presentation.
RESULTS
RESULTS
A total of 247 individuals with HTLV-1 infection had been reported in Spain since year 2008. The incidence has remained stable with 20-25 new diagnoses yearly. Women represented 62%. Only 12% were native Spaniards, most of whom were foreigners from Latin America (72.5%). Up to 57 (23%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (n = 24; 42.1%), T-cell lymphoma (n = 19; 33.3%), or
CONCLUSIONS
CONCLUSIONS
Given that 23% of new HTLV-1 diagnoses in Spain are symptomatic, underdiagnosis must be common. Although screening in blood banks mostly identifies asymptomatic Latin American carriers, a disproportionately high number of Spaniards and Africans are unveiled too late, that is, they already suffer from classic HTLV-1 illnesses.
Identifiants
pubmed: 30815504
doi: 10.1093/ofid/ofz036
pii: ofz036
pmc: PMC6386801
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz036Investigateurs
C Rodríguez
(C)
M Vera
(M)
J Del Romero
(J)
G Marcaida
(G)
M D Ocete
(MD)
E Caballero
(E)
I Molina
(I)
A Aguilera
(A)
J J Rodríguez-Calviño
(JJ)
D Navarro
(D)
C Rivero
(C)
M D Vilariño
(MD)
R Benito
(R)
S Algarate
(S)
J Gil
(J)
R Ortiz de Lejarazu
(R)
S Rojo
(S)
J M Eirós
(JM)
A San Miguel
(A)
C Manzardo
(C)
J M Miró
(JM)
J García
(J)
I Paz
(I)
E Poveda
(E)
E Calderón
(E)
D Escudero
(D)
M Trigo
(M)
J Diz
(J)
M García-Campello
(M)
M Rodríguez-Iglesias
(M)
A Hernández-Betancor
(A)
A M Martín
(AM)
J M Ramos
(JM)
A Gimeno
(A)
F Gutiérrez
(F)
J C Rodríguez
(JC)
V Sánchez
(V)
C Gómez-Hernando
(C)
G Cilla
(G)
E Pérez-Trallero
(E)
J López-Aldeguer
(J)
L Fernández-Pereira
(L)
J Niubó
(J)
M Hernández
(M)
A M López-Lirola
(AM)
J L Gómez-Sirvent
(JL)
L Force
(L)
C Cifuentes
(C)
S Pérez
(S)
L Morano
(L)
C Raya
(C)
A González-Praetorius
(A)
J L Pérez
(JL)
M Peñaranda
(M)
S Hernáez-Crespo
(S)
J M Montejo
(JM)
L Roc
(L)
A Martínez-Sapiña
(A)
I Viciana
(I)
T Cabezas
(T)
A Lozano
(A)
J M Fernández
(JM)
I García-Bermejo
(I)
G Gaspar
(G)
R García
(R)
M Górgolas
(M)
C Vegas
(C)
J Blas
(J)
P Miralles
(P)
M Valeiro
(M)
T Aldamiz
(T)
N Margall
(N)
C Guardia
(C)
E do Pico
(E)
I Polo
(I)
A Aguinaga
(A)
C Ezpeleta
(C)
S Sauleda
(S)
M Pirón
(M)
P Torres
(P)
R González
(R)
A Jiménez
(A)
L Blanco
(L)
A Suárez
(A)
I Rodríguez-Avial
(I)
A Pérez-Rivilla
(A)
P Parra
(P)
M Fernández
(M)
M Fernández-Alonso
(M)
A Treviño
(A)
S Requena
(S)
L Benítez-Gutiérrez
(L)
V Cuervas-Mons
(V)
C de Mendoza
(C)
P Barreiro
(P)
V Soriano
(V)
O Corral
(O)
F Gomez-Gallego
(F)
Références
Transplantation. 2003 Jan 15;75(1):102-4
pubmed: 12544880
J Clin Virol. 2011 Oct;52(2):119-22
pubmed: 21782504
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
AIDS Res Hum Retroviruses. 2014 Sep;30(9):856-62
pubmed: 24924996
Expert Rev Clin Immunol. 2014 Nov;10(11):1531-46
pubmed: 25340428
Transfus Clin Biol. 2016 Feb;23(1):13-9
pubmed: 26778839
Viruses. 2016 Feb 03;8(2):null
pubmed: 26848683
Antiviral Res. 2017 Jan;137:41-48
pubmed: 27840202
Blood. 2016 Dec 29;128(26):3029-3031
pubmed: 28034870
PLoS One. 2017 Feb 3;12(2):e0171303
pubmed: 28158226
Euro Surveill. 2017 May 18;22(20):null
pubmed: 28598325
AIDS. 2017 Jul 31;31(12):1653-1663
pubmed: 28700391
Cancer Sci. 2017 Dec;108(12):2478-2486
pubmed: 28905463
Vox Sang. 2017 Nov;112(8):723-732
pubmed: 28960337
Viruses. 2017 Dec 21;10(1):
pubmed: 29267225
Rev Med Virol. 2018 Mar;28(2):
pubmed: 29380451
Br J Haematol. 2019 Feb;184(4):688-689
pubmed: 29527675
J Neurovirol. 2018 Aug;24(4):523-525
pubmed: 29532443
Blood Adv. 2018 Mar 27;2(6):607-620
pubmed: 29545256
AIDS Rev. 2018;20(4):187-204
pubmed: 30548023
Nature. 1981 Nov 19;294(5838):268-71
pubmed: 6272125